Altunkeser BB, et al. - In this study involving 106 statin-naive patients with acute coronary syndrome, researchers compared serum oxidized low-density lipoprotein (oxidized-LDL) and proprotein convertase subtilisin kexin 9 (PCSK9) levels between high-dose atorvastatin- and rosuvastatin-treated patients. Patients were randomized 1:1 to atorvastatin (80 mg/day) or rosuvastatin (40 mg/day). Findings revealed that the observed impacts of atorvastatin and rosuvastatin treatment regimens on lipid parameters and PCSK9 levels were comparable; both the regimens led to similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similar increases in high-density lipoprotein cholesterol and PCSK9 levels.